• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[眼部与皮质类固醇的使用]

[Eye and corticosteroid's use].

作者信息

Fel Audrey, Aslangul Elisabeth, Le Jeunne Claire

机构信息

Assistance Publique-Hôpitaux de Paris, Hôtel-Dieu, université Paris Descartes, service de médecine interne, 75004 Paris, France.

出版信息

Presse Med. 2012 Apr;41(4):414-21. doi: 10.1016/j.lpm.2012.02.001. Epub 2012 Feb 28.

DOI:10.1016/j.lpm.2012.02.001
PMID:22377461
Abstract

Most common side effects of systemic corticosteroids are posterior subcapsular cataract and glaucoma. There is no way to prevent corticosteroid-induced cataract. The risk of these complications varies (cataract 11 to 15%; glaucoma 12.8%), and it depends on the dose, duration of administration and terrain. The discontinuation of corticosteroid therapy is required in cases of uncontrolled glaucoma by hypotonic treatment. Long-term topical or general steroids prescription has to be done after an ophthalmological examination. Indications of ophthalmic general corticosteroids are acute orbital and ocular inflammations. affecting the middle and posterior segments of the eye, or sclera when topical treatment is ineffective. When administered topically, only 5% of the delivered dose is absorbed by the anterior segment, distribution is almost zero in the middle and posterior segments of the eye.

摘要

全身用皮质类固醇最常见的副作用是后囊下白内障和青光眼。没有办法预防皮质类固醇诱发的白内障。这些并发症的风险各不相同(白内障为11%至15%;青光眼为12.8%),这取决于剂量、给药持续时间和个体情况。对于经低渗治疗眼压仍无法控制的青光眼患者,需要停用皮质类固醇治疗。长期局部或全身使用类固醇药物必须在眼科检查后进行。眼科全身用皮质类固醇的适应证为急性眼眶和眼部炎症,影响眼的中后段,或局部治疗无效时累及巩膜。局部给药时,仅5%的给药剂量被眼前段吸收,在眼的中后段分布几乎为零。

相似文献

1
[Eye and corticosteroid's use].[眼部与皮质类固醇的使用]
Presse Med. 2012 Apr;41(4):414-21. doi: 10.1016/j.lpm.2012.02.001. Epub 2012 Feb 28.
2
[Corticotherapy: a useful update].[皮质激素疗法:一次有益的更新]
Presse Med. 2012 Apr;41(4):368-9. doi: 10.1016/j.lpm.2012.01.024. Epub 2012 Feb 25.
3
Ocular side-effects of topical corticosteroids: what a dermatologist needs to know.局部用皮质类固醇的眼部副作用:皮肤科医生需要了解的内容。
Australas J Dermatol. 2015 Aug;56(3):164-9. doi: 10.1111/ajd.12292. Epub 2015 Mar 5.
4
Advances in ocular corticosteroid therapy.眼部皮质类固醇疗法的进展
Med Clin North Am. 1973 Sep;57(5):1167-77. doi: 10.1016/s0025-7125(16)32219-2.
5
[Ocular side-effects of corticotherapy (analysis of 3 cases)].
Dakar Med. 1989;34(1-4):161-5.
6
Dexamethasone for ocular inflammation.地塞米松治疗眼部炎症。
Expert Opin Pharmacother. 2011 May;12(7):1127-31. doi: 10.1517/14656566.2011.571209. Epub 2011 Apr 2.
7
Corticosteroid induced glaucoma and cataract.
Indian J Ophthalmol. 1981 Dec;29(4):377-9.
8
Locally administered ocular corticosteroids: benefits and risks.局部应用的眼部皮质类固醇:益处与风险。
Drug Saf. 2002;25(1):33-55. doi: 10.2165/00002018-200225010-00004.
9
[Ocular changes in rheumatic disease].[风湿性疾病中的眼部变化]
Minerva Med. 1978 Sep 30;69(46):3134-7.
10
[Corticosteroids and ophthalmology].[皮质类固醇与眼科]
Rev Prat. 1990 Feb 21;40(6):536-40.

引用本文的文献

1
Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety.系统性红斑狼疮的合成药物治疗:作用机制、疗效和安全性的潜在机制。
Medicina (Kaunas). 2022 Dec 27;59(1):56. doi: 10.3390/medicina59010056.
2
Case Report: A Promising Treatment Strategy for Noninfectious Uveitis.病例报告:非感染性葡萄膜炎的一种有前景的治疗策略。
Front Pharmacol. 2022 Jan 18;12:784860. doi: 10.3389/fphar.2021.784860. eCollection 2021.
3
Retinal thickness and microvascular alterations in the diagnosis of systemic lupus erythematosus: a new approach.
视网膜厚度和微血管改变在系统性红斑狼疮诊断中的应用:一种新方法。
Quant Imaging Med Surg. 2022 Jan;12(1):823-837. doi: 10.21037/qims-21-359.
4
Ocular Signs and Ocular Comorbidities in Monoclonal Gammopathy: Analysis of 80 Subjects.单克隆丙种球蛋白病的眼部体征和眼部合并症:80例受试者分析
J Ophthalmol. 2021 Jun 18;2021:9982875. doi: 10.1155/2021/9982875. eCollection 2021.
5
Agonistic 2-Adrenergic Receptor Autoantibodies Characterize the Aqueous Humor of Patients With Primary and Secondary Open-Angle Glaucoma.激动型 2-肾上腺素能受体自身抗体可用于原发性和继发性开角型青光眼患者房水的特征分析。
Front Immunol. 2021 May 5;12:550236. doi: 10.3389/fimmu.2021.550236. eCollection 2021.
6
Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation.用于治疗眼表炎症的局部眼用给药系统的设计进展及其生物药剂学评价
Pharmaceutics. 2020 Jun 19;12(6):570. doi: 10.3390/pharmaceutics12060570.
7
Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma.β2-肾上腺素能受体激活自身抗体可用于鉴别原发性和继发性青光眼患者。
Front Immunol. 2019 Oct 1;10:2112. doi: 10.3389/fimmu.2019.02112. eCollection 2019.
8
Systemic lupus erythematosus and ocular involvement: an overview.系统性红斑狼疮与眼部受累:概述。
Clin Exp Med. 2018 May;18(2):135-149. doi: 10.1007/s10238-017-0479-9. Epub 2017 Dec 14.
9
Risk factors for cataracts in systemic lupus erythematosus (SLE).系统性红斑狼疮(SLE)患者白内障的危险因素。
Rheumatol Int. 2015 Apr;35(4):701-8. doi: 10.1007/s00296-014-3129-5. Epub 2014 Sep 26.
10
Emerging therapies for noninfectious uveitis: what may be coming to the clinics.非感染性葡萄膜炎的新兴疗法:哪些疗法可能会应用于临床。
J Ophthalmol. 2014;2014:310329. doi: 10.1155/2014/310329. Epub 2014 Apr 24.